One such RTK, tyrosine-protein kinase receptor UFO (AXL), has been implicated for its role in resistance to imatinib and erlotinib in leukemia and non-small cell lung cancer, respectively [249,250]. This evidence concerns the gene AXL and non-small cell lung carcinoma.